Urologists saw their median compensation drop by 4.66% in 2010, recent survey results indicate.
Urologists saw their median compensation drop by 4.66% in 2010, recent survey results indicate.
Overall, primary and specialty care physicians reported mixed movement in compensation in 2010, according to results from the Medical Group Management Association’s physician compensation and production survey. Urologists earned $372,455, a decrease of 4.66% since 2009. Radiologists earned a median compensation of $471,253, a decrease of 1.58%, and physicians in internal medicine earned $205,379 in median compensation, an increase of 4.21% since 2009. Anesthesiologists and gastroenterologists reported decreased compensation while psychiatrists, dermatologists, neurologists, and general surgeons reported an increase.
Regional data included in the report reveal compensation discrepancies among physicians based on geographic location. In the Southern region, primary and specialty-care physicians reported the highest earnings at $216,170 and $404,000 respectively. Primary and specialty-care physicians in the Eastern section reported the lowest median compensation at $194,409 and $305,575, respectively.
"A number of factors may attribute to regional differences in physician compensation," said Jeffrey B. Milburn, MBA, of the MGMA. "The supply and demand for primary care or specialty physicians may influence compensation. A high level of competition between groups or specific specialties may provide an opportunity for payers to reduce reimbursement. In states where payers have little competition, reimbursement and subsequent physician compensation may be lower."
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.